The effect of ciprofibrate on gastric secretion in the rat
- 1 July 1988
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 40 (7) , 512-513
- https://doi.org/10.1111/j.2042-7158.1988.tb05289.x
Abstract
The potential of ciprofibrate to inhibit gastric secretion has been investigated in the rat. A significant gastric antisecretory effect was observed following a single oral administration of 300 and 500 mg kg−1 and following a single intraduodenal dose of 100, 300 and 500 mg kg−1. The toxicological significance of this finding is discussed in the light of a spate of recent publications linking changes in gastric morphology with hypergastrinaemia produced as a secondary effect of inhibition of acid secretion.This publication has 10 references indexed in Scilit:
- Plasma gastrin and gastric enterochromaffinlike cell activation and proliferationGastroenterology, 1986
- Antisecretory drugs and gastric cancer.BMJ, 1985
- Pharmacological basis for the induction of gastric carcinoid tumours in the rat by loxtidine, an unsurmountable histamine H2‐receptor blocking drugBritish Journal of Pharmacology, 1985
- Antisecretory drugs and gastric cancer.BMJ, 1985
- Ciprofibrate in the therapy of type II hypercholesterolemia A double-blind trialAtherosclerosis, 1982
- The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drugAtherosclerosis, 1979
- TUMORS IN MALE-RATS FED ETHYL CHLOROPHENOXYISOBUTYRATE, A HYPOLIPIDEMIC DRUG1979
- Clofibrate: antisecretory-antiulcer activity in the ratJournal of Pharmacy and Pharmacology, 1976
- A Quantitative Method for Measuring Spontaneous Gastric Secretion in the RatGastroenterology, 1954